Given the encouraging results obtained in the MSI subgroup of CRC patients treated with PD1 inhibitors, it seems that there is an undeniable value in evaluating checkpoint inhibitors in the specific subgroup of MSI BRAF-mt patients. Here, BRAF is linked to colorectal carcinoma.